A Phase 2A randomized, double-blind, placebo-controlled pilot trial of GM604 in patients with Amyotrophic Lateral Sclerosis (ALS Protocol GALS-001) and a single compassionate patient treatment (Protocol GALS-C)

Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease that lacks effective treatment options. Genervon has discovered and developed GM604 (GM6) as a potential ALS therapy. GM6 has been modeled upon an insulin receptor tyrosine kinase binding motoneuronotrophic factor wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Kindy, Mark, Lupinacci, Paul, Chau, Raymond, Shum, Tony, Ko, Dorothy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051227/
https://www.ncbi.nlm.nih.gov/pubmed/30057745
http://dx.doi.org/10.12688/f1000research.10519.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6051227/
https://www.ncbi.nlm.nih.gov/pubmed/30057745
http://dx.doi.org/10.12688/f1000research.10519.1

Ejemplares similares